SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: juneau_boy who wrote (422)4/3/2000 11:05:00 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3559
 
<<Question: Wouldn't it take years even with new genomic tools to get a drug to market from this discovery, and would'nt REGN have the obesity field to itself until then?>>

First, REGN needs solid AXOKINE PII phase results to convince investors that they have right drug for obesity.

Second, any competitor working on leptin signaling (or similar one), or downstream target is at least 2-3 years behind.

Miljenko